Translational and Clinical Studies

Working Group 6

Key outcomes for WG 6 are the rapid translation of results from the other WGs into clinical applications.

In addition to the established clinical indications for MR antagonists such as hypertension and systolic heart failure, contributing researchers in the ADMIRE consortium have identified MR activation either by aldosterone or glucocorticoids to be involved in many diseases including

  •     Iinflammatory diseases
  •     Myocardial infarct wound healing
  •     Diastolic heart failure
  •     Renal insufficiency
  •     Obesity
  •     Diabetes
  •     Epidermal atrophy
  •     Certain ocular diseases.

Participating investigators of WG6 are highly experienced in designing and coordinating small explorative as well as large definitive clinical trials in cooperation with industrial partners which will

  •     Identify the contribution of aldosterone/MR activation in human pathophysiology
  •     Test potential novel applications of MR antagonists in appropriate patient populations
  •     Generate the evidence leading to approval for novel clinical indications.

The contributing researchers of WG6 provide technical and administrative platforms to be shared in the COST action for design, organisation and planning of clinical investigations, ensuring accordance with good clinical practice and legal and ethical obligations, the monitoring of patients, and the management of any unexpected adverse effects.

An important aim of WG6 is to better identify patients suited for MR antagonist therapy both in the established indications but also in potential novel indications by identifying and validating susceptibility markers (genotype) or biological markers of MR activation (biomarkers). This will also allow a more personalized medicine where patients treated with MR antagonists will be carefully monitored to maximize desired therapeutic effects and to minimize unwanted side effects. Together with the current strong interest of several pharmaceutical companies to develop novel non-steroidal MR antagonists with potentially fewer and lesser side effects and hopefully better specificity to several organs and tissues, the outstanding experience of the translational and clinical researchers in the WP6 of the COST Action will stimulate in a timely fashion the creation of a scientific highly interactive European environment to rapidly expand the knowledge and the clinical application of MR antagonist treatment.

Working Group 6 members

  • Johann Bauersachs, WG Leader, Germany
  • Michael Azizi, France
  • Brian Walker, United Kingdom
  • Paloma Manea, Romania
  • Gian Paolo Rossi, Italy
  • Leonardo Sechi, Italy
  • Faiez Zannad, France

Research Group 1

J BauersachsHead: Prof. Dr. Johann Bauersachs, Director, Department of Cardiology and Angiology, Centre for Internal Medicine, Hannover Medical School, Germany
Keywords: Adrenocorticol steroid receptors, myocardial ischemia, rodent models of myocardial infarction
Click here for more information on Prof Bauersach’s research

Research Group 2

G RossiHead: Professor Gian Paolo Rossi, Department of Medicine-DIMED, Internal Medicine 4 and Center of Hypertension, Univerity of Padua, Italy
Keywords: Adrenocorticol steroid receptors, myocardial ischemia, rodent models of myocardial infarction
Click here for more information on Prof Rossi’s research

Research Group 3

Brian WalkerHead: Professor Brian Walker, Professor of Endocrinology & Head of University/BHF Centre for Cardiovascular Science, University of Edinburgh, UK
Keywords: Cortisol metabolism, metabolic syndrome and cardiovascular disease.
Click here to find out more about Prof Walker’s research